Efficacy of continuous ADT and correlation to nadir serum T levels

We had “missed” a poster presented at the recent meeting of the European Urology Association that appears to “put to bed” — in a positive fashion — the question of a relationship between nadir serum testosterone (T) levels in men on continuous androgen deprivation therapy (ADT) and the long-term effectiveness of continuous ADT. … READ MORE …

What is the appropriate serum T threshold for medical “castration”?

For many years, the formal threshold level of serum testosterone (T) used to define medical “castration” has been < 50 ng/dl. However, it is widely recognized that this level is probably not low enough to accurately define a medically castrate state. … READ MORE …

Baseline serum androgen levels and responses to abiraterone acetate

Baseline levels of serum androgens were predictive for clinical response to treatment in the Phase III clinical trial of abiraterone acetate in men with chemotherapy-refractory, metastatic, castration-resistant prostate cancer (mCRPC), according to a new article in the Journal of Clinical Oncology. … READ MORE …

A very different way to project risk for clinically significant prostate cancer?

We don’t want to suggest that the recent paper by a Japanese research team in the journal Andrology is necessarily going to revolutionize the diagnosis of clinically significant prostate cancer. A great deal more work would be required to justify the hypothesis that they put forward. On the other hand, their hypothesis is definitely interesting. … READ MORE …

Better identification of potentially good responders to prostate cancer immunotherapy

A paper just published in Clinical Cancer Research has suggested that — at least for one immunotherapeutic agent (“vaccine”) in development for the treatment of advanced prostate cancer — it may be possible to define a subgroup of men who are more likely to respond well to treatment than others. … READ MORE …

Sexual function and serum T levels, before, on, and after 9 months of ADT

As many readers of this news service will be aware, good data on the recovery of libido and sexual function after a period of androgen deprivation therapy (ADT) are limited. We have long known that such recovery is variable, and we also know that it can take time, but sound data from a large cohort of patients has been “missing in action,” so to speak. A new paper by Ng et al. has now remedied this problem. … READ MORE …

Recovery of serum T levels after short-term LHRH agonist therapy

An article in the June issue of the Canadian Urological Association Journal offers preliminary evidence from a randomized clinical trial that men treated for 6 months with a short-acting LHRH agonist may recover normal serum testosterone (T) levels faster than those treated for the same time with a long-acting LHRH agonist. … READ MORE …

Follow

Get every new post delivered to your Inbox.

Join 1,142 other followers